#LCSM Chat Topic 5/4 — The PDQ on MTBs: Why are multidisciplinary tumor boards important in #lungcancer?
Lung cancer is a complicated disease. Diagnosing and treating complex cases can require skills that cross a variety of medical specialties. Larger medical centers and hospitals may decide to discuss complex cases in tumor boards that include physicians that represent a variety of medical specialties. Our May 4, 2017, #LCSM Chat (at 8pm Eastern, 5pm Pacific) will focus on defining what a multidisciplinary tumor board (MTB) does, who is involved, and why MTB are important in the treatment of lung cancer. The National Cancer Institute defines a tumor board review as: A… Read More
#LCSM Chat Topic 4/6: Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?
Our topic for the next #LCSM Chat on Thursday, April 6th at 5 PM Pacific/ 8 PM Eastern is “Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD) In its most recent budget outline, the Trump administration is looking to propose an 18% cut to the National Institute of Health’s (NIH; @NIH) $31.7 billion budget (#trumpbudget). In addition to this funding cut, the Trump administration proposes to 1) reorganize the current NIH institute structure and 2)… Read More
#LCSM Chat Topic 3/9: Test Tumors to Target Lung Cancer
Our topic for the next #LCSM Chat on Thursday, March 9th at 5 PM Pacific (8 PM Eastern) is “Test Tumors to Target Lung Cancer.” Lung cancer treatments are evolving rapidly. Some newer treatments require testing to identify patients who are likely to respond to the drugs. The testing looks for certain biomarkers on the patient’s cancer tumors, like alterations in the tumor cells’ genes. Patients whose tumors test positive may be able to take approved targeted therapy drugs that are usually more effective and more tolerable than chemo. A substantial percentage… Read More
#LCSM 
You must be logged in to post a comment.